Italian drugmaker Newron Pharmaceuticals and EA Pharma, a subsidiary of Japan’s Eisai, today have entered into a license agreement to develop, manufacture and...
15.02.2018
- Boehringer Ingelheim said it plans to shift the focus of its investigational compound BI 409306 to ongoing clinical trials with schizophrenia patients after the drug failed to...
20.05.2015
- US pharmaceutical giant Johnson & Johnson has agreed to pay $7.8 million to settle a lawsuit over the marketing of its antipsychotic drug Risperdal to doctors in the US state of...
